Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Q1 2023 Earnings Call dated May. 10, 2023.
Corporate Participants:
Andrea Flynn — Vice President and Head, Investor Relations
Bruce C. Cozadd — Chairman and Chief Executive Officer
Daniel N. Swisher — President and Chief Operating Officer
Robert Iannone — Executive Vice President, Global Head of Research and Development
Renee Gala — Executive Vice President and Chief Financial Officer
Kim Sablich — Executive Vice President and General Manager, United States
Analysts:
Unidentified Participant — — Analyst
Marc Goodman — SVB Leerink — Analyst
Jason Gerberry — Bank of America — Analyst
Joseph Thome — TD Cowen — Analyst
Brandon Folkes — Cantor Fitzgerald — Analyst
Amy Fadia — Needham and Company — Analyst
Balaji Prasad — Barclays — Analyst
Madhu Kumar — Goldman Sachs — Analyst
Gregory Renza — RBC Capital Markets — Analyst
Ivory — Jefferies — Analyst
Greg Fraser — Truist Securities — Analyst
Jeff Hung — Morgan Stanley — Analyst
Ash Verma — UBS — Analyst
David Amsellem — Piper Sandler — Analyst
Presentation:
Operator
Good day, and thank you for standing by. Welcome to the Q1 2023 Jazz Pharmaceuticals Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Andrea Flynn, Vice President and Head of Investor Relations. Please go ahead.
Andrea Flynn — Vice President and Head, Investor Relations
Thank you, operator, and good afternoon, everyone. Today, Jazz Pharmaceuticals reported first-quarter 2023 financial results. The slide presentation accompanying this webcast is available on the Investors section of our website. Investors may also refer to the press release we issued earlier today, which is also posted to our website. On the call today are Bruce Cozadd, Chairman and Chief Executive Officer; Renee Gala, Executive Vice President and Chief Financial Officer; Dan Swisher, President and Chief Operating Officer; and Rob Iannone, Executive Vice President, Global Head of R&D. Kim Sablich, Executive Vice President and General Manager United States will join the team for Q&A.
On Slide 2, I’d like to remind you that today’s webcast includes forward-looking statements. Such as those related to our future financial and operating results, growth potential and anticipated development and commercialization milestones and goals, which involve risks and uncertainties that could cause actual events, performance and results to differ materially from those contained in these forward-looking statements. We encourage you to review the statements contained in today’s press release, in our slide deck and in our latest SEC disclosure document, which identify certain factors that may cause the Company’s actual events, performance and results to differ materially from those contained in these forward-looking statements made on today’s webcast. We undertake no duty or obligation to update our forward-looking statements.
Turning to Slide 3 on this webcast we’ll discuss non-GAAP financial measures. Descriptions of these non-GAAP financial measures and reconciliation of GAAP to non-GAAP financial measures are included in today’s press release and the slide presentation available on the Investors section of our website.
I’ll now turn the call over to Bruce.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Thanks, Andrea. Good afternoon, everyone, and thank you for joining us today. I’ll start on Slide 5. In the first quarter of 2023, we once again delivered strong commercial results, continue to advance our pipeline, and built on our record of operational excellence. Our results for the quarter underscore the durability and growth of our core commercial products and our enhanced R&D capabilities.
On the commercial front, our focus on execution continues to drive key product sales, headlined by the strong performance of low-sodium Xywav. We’re especially pleased that physicians and patients continue to choose Xywav even as a high sodium oxybate authorized generic or AG entered the market. We continue to expect that Xywav will both grow and remain the oxybate of choice in 2023 even with the availability of high sodium oxybate AG and branded fixed-dose high sodium oxybate. Xywav active patients grew in both narcolepsy and idiopathic hypersomnia or IH in the first quarter and our efforts to educate prescribers and patients about the benefits of Xywav remain effective and are resonating in the market. Xywav is now annualizing at more than $1 billion in net product sales, making our largest product by net sales, and as outlined in Vision 2025, we anticipate our oxybate franchise will generate $2 billion in revenue in 2025.
We saw a significant year-over-year growth in-product sales for Epidiolex. Importantly outside the US, we have now launched in all five key European markets. Demand for Rylaze remain strong in the U.S. with potential European approval later this year. Zepzelca remains the treatment of choice in second-line small-cell lung cancer and longer-term our ongoing efforts to explore Zepzelca in several new patient populations, including first-line small-cell lung cancer may open up opportunities for meaningful growth.
Moving to R&D. We continue to advance multiple investigational therapies in our pipeline and expect to have at least three late-stage readouts by the end of 2024, including JZP 150 and post-traumatic stress disorder, suvecaltamide in essential tremor and zanidatamab in first-line gastroesophageal adenocarcinoma or GEA. On the operational side, our strong execution drove significant top and bottom-line growth in the first quarter compared to the prior year. We have a business that continues to generate meaningful cash flow in line with our disciplined capital allocation, we continue to invest in areas of our business that we believe will drive the most benefit for patients and value for shareholders, including our robust pipeline with more than 20 novel candidates across neuroscience, oncology and cannabinoids. We are reaffirming our 2023 guidance, which Renee will discuss in more detail.
Turning to Slide 6, Vision 2025 remains our strategic Northstar, which we believe will deliver sustainable growth and enhanced value. We have made meaningful progress in all three areas of Vision 2025 and believe we are well-positioned to achieve these important milestones, each of which are critical to our transformation into a high-growth global biopharma leader.
I’ll now turn the call over to Dan to review our commercial performance, after which Rob will share an update on our R&D progress, Renee will provide a financial overview and then we’ll open the call to Q&A, Dan?
Daniel N. Swisher — President and Chief Operating Officer
Thanks, Chris. I’m excited to share the continued progress across our commercial portfolio. I’ll begin on Slide 8 with neuroscience and our oxybate franchise. We remain confident in the durability of our oxybate franchise and have established low-sodium Xywav as the oxybate treatment of choice. Xywav became our largest product by net product sales as of the fourth quarter of 2022, and is annualizing at more than $1 billion as a result of continued adoption of both narcolepsy and IH. In the first quarter, average active Jazz oxybate patients increased to approximately 17,400, representing growth of approximately 5%. And total oxybate revenues, including royalties from high sodium oxybate AG grew by approximately 6% compared to the year prior.
In narcolepsy, we continue to focus on educating patients and prescribers on the benefits of reducing sodium intake and this message is resonating. We were very pleased with performance in the first quarter and exited 1Q 2003 with approximately 9,050 narcolepsy patients taking Xywav, an increase of approximately 500 patients from the fourth quarter of 2022. In IH, we see continued growth of new prescribers and exiting the first-quarter, there were approximately 2,000 IH patients taking Xywav. IH is a 24-hours sleep disorder and Xywav is the first and only treatment approved by FDA to treat the full condition of IH. Importantly, it has been studied across the multiple symptoms of IH. Our field force remains focused on educating prescribers on the importance of proper diagnosis and identifying appropriate patients for Xywav therapy and the recent Jazz survey of sleep specialists indicate that approximately 70% anticipate increasing their prescribing over the next six months.
Slide 9 highlights the compelling low-sodium health benefits we are sharing with healthcare professionals and patients. Narcolepsy is a debilitating chronic condition and we have focused on education around the lifelong burden of high sodium intake for narcolepsy patients, who live with an increased risk of cardiovascular comorbidities. Xywav is the only approved low sodium oxybate and has 92% less sodium than high sodium oxybates. The American Heart Association recommends a maximum of 1,500 milligrams of sodium per day. Xywav has a 100 to a 140 milligrams, a reduction of 1,000 to 1,500 milligrams in sodium per day compared to-high sodium oxybates. This has significant potential health benefits, including lower blood pressure and improved cardiovascular health.
To add to the literature on sodium impact, we presented data at this year’s American Academy of Neurology meeting that showed narcolepsy patients treated with high Sterling oxybate had a higher-risk of new onset hypertension diagnosis or anti-hypertensive medication initiation within a 180 days of starting therapy. When compared to a matched control group of narcolepsy patients not being treated with high sodium oxybate. In fact, the risk of those taking high sodium oxybate was approximately twice that of the control group.
With regards to oxybate competition a high sodium oxybate AG was launched in January and we anticipate additional AG and branded fixed-dose high sodium oxybate competition in the coming months. With competition now in the marketplace, I’ll share a few key takeaways based on our experience in the first quarter. First, we continue to build on the successful launch of Xywav, it remains the only low-sodium oxybate available to patients and we expect it to be the only oxybate indicated for IH for the foreseeable future.
Second, we expect that Xywav will both grow and remain the oxybate of choice in 2023 even with the availability of high-sodium oxybates. I’ll highlight that the large majority of narcolepsy patients beginning oxybate therapy in the first-quarter shows Xywav over a high sodium oxybate. And we expect to continue to see patients transition from those both Xyrem and high sodium oxybate AG to Xywav.
Third, we believe that the majority of patients and healthcare providers will continue to prioritize long-term health when evaluating oxybate therapy. FDA continues to recognize seven years of orphan drug exclusivity through July 2027 for Xywav in narcolepsy. FDA has also recognized the difference in sodium content between Xywav and Lumryz a fixed-dose high sodium oxybate is likely to be clinically meaningful in all patients with narcolepsy and that Xywav is safer than Lumryz in all such patients. I’ll also note that branded fixed-dose high sodium oxybates has the same sodium content as Xyrem and the high sodium oxybate AG. And Xywav is the only approved oxybate therapy that does not carry a warning and precaution related to high sodium intake. All of these factors give us confidence that Xywav is a durable product that we believe will continue to be a core growth driver for Jazz.
Moving to slide 10, we are pleased with the continued growth of Epidiolex with net product sales in the first quarter 2003, growing by 20% year-over-year to $189 million. Growth was driven by underlying demand in the U.S., and expansion to new markets outside the U.S. and we are seeing increasing use of Epidiolex earlier in the treatment algorithm. We continue to see seasonality in ordering patterns in the U.S. with a combination of a more gradual build-in inventory over the second half of the year and insurance plan resets with payers impacting the first quarter, not dissimilar to what we’ve seen historically with oxybate.
Turning to Slide 11, we are building on our solid foundation to capitalize on additional opportunities we see to drive up Epidiolex growth. We’ve recently launched a number of initiatives, including educational efforts focused on optimal dosing and caregiver-reported outcomes of Epidiolex treatment, including seizure behavior and cognition data from the BECOME survey. These new initiatives are complemented by the compelling data presented last year for use of Epidiolex in combination with Clobazam. Our commercial team also has an enhanced focus on further penetration into the adult setting. We remain focused on growing Epidiolex outside the U.S. We have now launched in all five key European markets. And while it’s early, we are very encouraged by uptake in those markets with pricing and access remaining strong.
Moving to Slide 12. Net product sales for Rylaze were $86 million for the first quarter, a 58% increase year-over-year. Based on the availability of Rylaze healthcare providers have indicated they are returning to best clinical practice and switching therapy at the first signs of hypersensitivity. The approval of Monday, Wednesday, Friday dosing allows for a dosing schedule that is more in line with preferred clinical practice. Rylaze is maintaining strong momentum in pediatric oncology protocols and it’s been almost universally adopted in this setting.
We are also encouraged to see that there is an increasing use of Rylaze in the treatment of adolescents and young adults or the AYA market, which is an area of increased emphasis for us in 2023. Outside of U.S., we submitted a marketing authorization application to the European Medicines Agency in May 2022. We are also continuing to evaluate patient needs in other geographies.
Slide 13 highlights that we have rapidly established Zepzelca as the treatment of choice in second-line small-cell lung cancer. Zepzelca net product sales increased 13% to $67 million in first quarter ’23 compared to the same-period in 2022, Rob will discuss our development plans for Zepzelca, which also includes trials in first-line small-cell lung cancer and other tumor types, providing the opportunity for meaningful future growth in new patient populations.
Now I will turn the call over to Rob for an update on our pipeline and upcoming milestones. Rob?
Robert Iannone — Executive Vice President, Global Head of Research and Development
Thanks, Dan. Starting on Slide 15, we have detailed key clinical programs in our pipeline. Our team is energized by the advances we’ve made and we’re looking forward to late-stage data readouts from at least three clinical-stage programs in 2023 and 2024 JZP150 in PTSD. Suvecaltamide in essential tremor and zanidatamab or zadi in GEA. I’ll highlight several programs in more detail shortly. First, I want to touch on a few key points as we look across the breadth of the pipeline.
Starting with neuroscience, development is ongoing in our Phase-2 PTSD trial for JZP150. The top-line data expected late this year. We are also advancing trials for suvecaltamide in both essential tremor or ET. And Parkinson’s disease tremor. The top-line data from the ET trial expected in the first half of 2024. In our orexin-2 receptor agonist or JZP441 Phase 1 program, we anticipate initial proof-of-concept in healthy volunteers this year. JZP441 has the potential to treat narcolepsy, high age as well as other sleep disorders.
Moving to oncology. Zanidatamab is a priority program for us and we are committed to bringing this novel therapy to patients. In late April, we amended our agreement with Zymeworks, and are excited to welcome new colleagues who are focused on zanidatamab at Zymeworks to Jazz. This allows us to benefit from their wealth of knowledge and expertise as we look to bring Zanidatamab to the market as rapidly as possible and explore other opportunities beyond BTC and GEA.
For Zepzelca, we expect to complete enrollment this year for the ongoing Phase 3 trial to evaluate Zepzelca in combination with Tecentriq in first-line extensive-stage small-cell lung cancer.
Turning to Slide 16. I will discuss zanidatamab in more detail. Zanidatamab is a novel HER2-targeted bispecific antibody with biparatopic binding and the potential to transform the current standard-of-care in multiple HER2-expressing cancers. As an oncologist, I’m impressed to see the monotherapy activity with zani across multiple HER2-expressing tumor types, including cases resistant to prior HER2 therapies. The most advanced clinical work with zani is in biliary tract cancers or BTC and gastroesophageal adenocarcinoma or GEA. These are both cancers with significant unmet need and poor outcomes with current standards of care.
As a reminder, last year we and our partner Zymeworks reported positive top-line results from a pivotal Phase 2b trial evaluating zanidatamab as monotherapy in patients with previously treated HER2 amplified and expressing BTC. In the trial, 41% of these patients with BTC achieved an objective response as assessed by blinded independent center review. By contrast, standard-of-care chemotherapy in second-line DTC would be expected to have an objective response rate of less than 10%.
Currently, there are no HER2-targeted therapies approved for the treatment of BTC. And we are in dialog with the FDA regarding the potential regulatory path forward for zani and BTC. We’re please the data from this trial have been accepted as an oral presentation at ASCO this year. For those of you interested in more detail on those data, I hope you will join us for the KOL webcast we are hosting following that presentation. We are also progressing our program in GEA. At the January ASCO GI Conference, the first zanidatamab overall survival data were presented from a Phase 2 trial evaluating zanidatamab in combination with chemotherapy in first-line patients with HER2 expressing metastatic GEA.
The preliminary results showed that the median overall survival had not yet been reached. With an 18-month survival rate of 84%, the overall survival findings in this trial are compelling given that historically reported overall survival rate for the currently approved standard-of-care is a median of 14 months. These results show zanidatamab’s potential as a foundational treatment for patients with HER2 positive GEA. And we look-forward to additional data from the ongoing pivotal Phase 3 GEA trial expected to readout in 2024, which may support US and global regulatory submissions.
Since we acquired zanidatamab our confidence in this program has only grown based on positive data from in both BTC and GEA. And while our initial focus is on those two tumor types, we believe zanidatamab has the potential to transform the current standard-of-care in multiple HER2 expressing cancers. To that end, we’re excited that zani was added to the I-SPY breast cancer platform this year. In addition, we have multiple early-stage trials, assessing zanidatamab’s clinical potential in a range of tumor types, and are actively evaluating opportunities to pursue additional label indications.
Turning to Slide 17, I’d like to highlight suvecaltamide, which is a highly selective and state dependent modulator of T-type calcium channels in clinical development for the treatment of essential tremor or ITI and Parkinson’s disease tremor. Top-line data readout for the ET trial is anticipated in the first-half of 2024, so I’ll focus my comments today on that indication. There is a high unmet need for ET treatment with no new medicines approved in over 50 years. ET can be highly debilitating with significant effects on patients’ quality-of-life and activities of daily living, such as eating, drinking, dressing, shaving and writing and can lead to substantial impairment on physical functioning.
Some patients also experienced cognitive deficits, anxiety, social phobia, depression and sleep disturbances. In the U.S. and key European markets, there are approximately 2 million diagnosed patients with a prevalence estimated at $11 million.
Slide 18 illustrates suvecaltamide’s differentiated mechanism of action. Well, the exact underlying pathophysiology of ET is not clear, there is strong evidence to support the role of T-type calcium channels. T-type calcium channels regulate the balance of calcium ions. Acting as a gatekeeper to have ions both enter and leave the cell membrane. In some pathologic states such as ET increased activation of these channels leads to excessive rhythmic signaling and a prompt tremor. The high selectivity of suvecaltamide for T-type calcium channels make it a promising candidate for the treatment of ET.
Importantly, suvecaltamide is differentiated from other T-type calcium channel blockers in development as it is state dependent. Meaning that it targets channels under conditions of hyperexcitability while sparing the form of the channel important for normal neuronal signaling.
Slide 19 provides an overview of the suvecaltamide ET Phase 2b trial design. Approximately 400 participants with moderate-to-severe ET will be treated with one of three dose levels of suvecaltamide or placebo for 12 weeks. Based on results from our prior Phase 2a proof-of-concept trial known as TCOM as well as FDA feedback. The primary endpoint being used in this trial is a change from baseline to week 12 on a composite of the tremor research group essential tremor rating assessment scale known as TETRAS. Two composites measure is composed of items from two scales 11 items from the TETRAS activities of daily living, which includes measures such as eating with a spoon, hygiene and using keys. And two items from the TETRAS performance scale, which represent handwriting and drawing in a archimede spiral which was depicted on Slide 17.
We conducted post-talk analysis on TCOM, which was a four-week randomized double-blind placebo-controlled study to better understand the treatment effect with the TETRAS composites endpoint. We believe that our ongoing Phase 2b trial has been optimally designed to use the Phase 2a learnings. And then an appropriate patient population, primary endpoint and study duration have been selected to adequately evaluate the safety and efficacy of suvecaltamide across three dose levels.
On Slide 20, we’ve highlighted several key aspects of our program exploring JZP150 for the treatment of PTSD. Psychiatric disorder that affects millions of people. Patients frequently have uncontrolled symptoms that impact their ability to perform activities of daily living and social function. PTSD effects upto 8% of adults during their lifetime and is associated with significant morbidity and mortality. There haven’t been any new medicines approved for the treatment of PTSD in over two decades. Current standard-of-care includes cognitive behavior therapy with SSRIs and SNRIs used as first-line pharmacotherapy treatments. However, response rates to pharmacologic treatments rarely exceed 60% and even fewer patients achieved clinical remission. JZP150 is potent, selective and irreversible inhibitor of fatty acid amide hydrolase or FAAH. This is a novel mechanism-of-action to potentially target the underlying pathophysiology in core symptoms of PTSD. We expect top-line data from this trial late this year.
Slide 21 provides an overview of our Zepzelca first-line small-cell lung cancer program. Small-cell lung cancer patients have particularly poor outcomes with a five-year overall survival rate of less than 10%. Currently, Zepzelca is indicated to treat patients in the second-line setting. But we see a clear mechanistic rationale for Zepzelca to potentially increase the duration of response in the first-line setting as maintenance therapy in combination with the standard-of-care It’s the chemotherapy plus a PD-L1 inhibitor.
We have an ongoing first-line trial being run in collaboration with Roche to evaluate Zepzelca in this setting with chemotherapy plus Tecentriq or atezolizumab. The trial design is outlined on the bottom portion of the slide, and we expect to complete enrollment by the end of the year.
Now. I will turn the call over to Renee for a financial update. Renee?
Renee Gala — Executive Vice President and Chief Financial Officer
Thanks, Rob. I’ll start with our top and bottom line results on Slide 23. As a reminder, our full financial results are available in our press release and 10-Q. In the first quarter of 2023, we recorded impressive year-over-year revenue of 10%, achieving $893 million in total revenues. This was driven by growth of our key products in both neuroscience and oncology, including year-over-year double-digit growth of Xywav, Epidiolex and Rylaze.
Our disciplined capital allocation and focus on operational excellence drove adjusted net income of $285 million, growing broadly in line with our revenues compared to the same period in 2022. We continue to generate significant cash from our business, recording more than $320 million of cash from operations in the first quarter of 2023, an increase of 53% compared to the first quarter of 2022.
With healthy cash flows and a strong balance sheet, we have strategic flexibility to invest in growth drivers within our current business as well as corporate development opportunities. Corporate development is an important component of Vision 2025, and we are actively assessing opportunities that we believe will deliver innovation for patients and contribute to building a sustainable business that provides meaningful returns to shareholders.
Turning to Slide 24. We are reiterating the 2023 revenue guidance we provided in March. We are executing in line with our expectations and are confident in meeting those targets. The guidance reflects our strong performance in the first quarter, our expectations around the durability of our oxybate franchise and anticipated growth across our key products. Our total revenue guidance range for 2023 is $3.675 billion to $3.875 billion, positioning us for year-over-year total revenue growth.
Our 2023 guidance for neuroscience of $2.675 billion to $2.825 billion incorporates expected growth for both Xywav and Epidiolex as well as the continued decline in Xyrem due to robust Xywav adoption and the introduction of competitive high sodium oxybates. As a reminder, our neuroscience guidance also includes high sodium oxybate AG royalties, which are recognized within total revenues under royalties, not under neuroscience net product sales.
Due to the royalty structure within our AG agreement with Hikma, we expect our royalties to be significantly higher in the second half of 2023 relative to the first half. As a reminder, in the first half of 2023, while Hikma maintains exclusive rights to distribute high sodium oxybate AG, the royalty rate paid to Jazz is tiered and wide-ranging, starting at 10% and going all the way to 90% based on the volume of AG units sold as a percentage of total oxybate units, with the total referring to Xywav, Xyrem and high sodium oxybate AG.
During the second half of 2023, the royalty rate to Jazz becomes fixed at a rate where we and Hikma both have substantial economics regardless of the AG volumes. Our oncology guidance reflects expectations of continued double-digit growth for this franchise with a revenue range of $950 million to $1.05 billion, resulting in a midpoint of $1 billion.
Continuing on Slide 25, our SG&A guidance for 2023 is a reduction compared to 2022, and we are tracking through the first quarter as expected. As we noted in our last quarterly update, our R&D guidance of $700 million at the midpoint represents enhanced investment over 2022, reflecting the growth and maturation of our pipline, as Rob noted earlier in the call. On the bottom line, we expect to continue to deliver strong adjusted net income with 37% growth at the midpoint and a guidance range of $1.24 billion to $1.31 billion. The midpoints of our financial guidance imply an adjusted operating margin of approximately 46% for the year. We’ll continue to prioritize commercial, R&D and corporate development efforts that we believe will deliver the most value, leveraging our cash generation to invest in our business, improve our bottom line and deliver strong shareholder returns.
With our strategic investments, expanding product portfolio, R&D progress and focus on operational excellence, we believe we are well-positioned to achieve Vision 2025. And deliver further diversification, sustainable growth and enhanced value to patients and to shareholders.
I’d now like to turn the call back to Bruce.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Thanks, Renee. I’ll conclude our prepared remarks on Slide 27. We started 2023 with significant momentum, and I’m pleased to report that we’ve continued making strong progress in the first quarter of 2023. On the commercial front, we’ve successfully launched multiple products over the past several years, which are now demonstrating strong and durable performance.
Our pipeline is more robust than it’s ever been in the company’s history. And we have at least three anticipated late-stage data readouts through 2024 that have the potential to continue to diversify and transform our business. We also remain focused on strategic capital allocation. With our strong cash flow, balance sheet and margins, we have the flexibility to make significant investments across commercial, pipeline and corporate development to drive sustainable growth and enhanced value.
That concludes our prepared remarks. I’d now like to turn the call over to the operator to open the line for Q&A.
Questions and Answers:
Operator
[Operator Instructions] And our first question comes from the line of Jessica Fye with JPMorgan. Your line is now open.
Unidentified Participant — — Analyst
Hey guys, this is. Nasan [Phonetic] on for Jessica Fye. Can you give us some color on how the introduction of the Xyrem AG is play-out versus what your expectations are? And then second, what kind of business development is most interesting to you in this current environment? Thank you.
Bruce C. Cozadd — Chairman and Chief Executive Officer
All right. Well, let’s start with the question about the authorized generic. And then Renee, maybe you can jump in to handle corporate development. The most important thing to say about our first quarter with an AG on the market is that it’s played out very much the way we thought it would thus far. We have a new entrant in the high sodium category when we are obviously growing Xywav as the only low-sodium product, both in narcolepsy and in idiopathic hypersomnia, where it remains the only approved product without an AG generic.
The ability to grow in both narcolepsy and idiopathic hypersomnia in the face of the AG generic, I think, is consistent with what we had guided to, and you saw us reaffirm our overall guidance for the year based on that first quarter experience. Renee, you want to take corporate development?
Renee Gala — Executive Vice President and Chief Financial Officer
Sure. Thanks, Bruce. So corporate development continues to be an important priority for us, as I mentioned in our prepared remarks. In terms of the assets we are interested in, we are squarely focused on commercial and near-commercial assets as part of our Vision 2025 revenue goals. We think that zanidatamab can certainly contribute to that goal, but it will not fully cover it. We also are looking at pipeline assets. We have a rather robust pipeline right now that we’re pushing forward. And we think we can continue to look at bringing in assets that can complement that pipeline.
We do believe there are some good opportunities for us to transact across both of those areas. With respect to commercial or near commercial assets, to be clear, we’re not going to overpay for assets, nor do we think that we need to in this environment. So sitting here today, there are multiple opportunities we’re interested in, and we’re quite busy within that team. And then just to get a bit more specific in terms of the types of assets, we really tend to focus on areas of great unmet need where we think we can have a really meaningful impact for patients, where there’s an addressable commercial call point that enables us to leverage our expertise, our global footprint and then create a durable revenue stream for the company.
We’re largely focused on neuroscience and oncology areas where we currently operate already. But certainly, we’re also exploring rare and orphan areas outside of those two therapeutic areas, given the vast majority of our current commercial products are currently serving rare or orphan disease population. So there’s certainly applicable expertise that we have developed there. So we’re excited. We think there’s a lot of opportunity. We’re well positioned also from a financial perspective to be able to transact.
Operator
Your next question comes from the line of Marc Goodman with SVB Leerink. Your line is now open.
Marc Goodman — SVB Leerink — Analyst
Yes, hi. Could you give us a little more color on what’s going on in the IH market? We know the number of patients that you moved from last quarter to this quarter, but just some color, anecdotal information. Anything you can help us with understand what’s happening behind the scenes? Thanks.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes, Marc, let me turn that question over Kim.
Kim Sablich — Executive Vice President and General Manager, United States
Yes. So we are continuing to see the growth in idiopathic hypersomnia is quite compelling with 2,000 active patients exiting the first quarter. And when you look underneath that, we see that we’re continuing to bring new prescribers onboard and creating a larger prescribe base, which is great. And what we see is that as prescribers get experience with the product, Dan mentioned in a survey of sleep specialists, 70% out there indicating that they’re going to increase their prescribing of Xywav for IH over the next six months.
So good indicators of both the experience that they’re having to date as well as their attentions in the future. But do keep in mind that Xywav remains the only FDA-approved treatment option for adults with idiopathic hypersomnia, which is a rare multiple-symptom sleep disorder and the only treatment studied across the multiple symptoms of IH. And we’re really still just building this kind of nonexisting market. And as a result, we’re executing a comprehensive disease education campaign both for healthcare providers as well as patients across multiple channels and platforms. And our emphasis really is on educating prescribers on the importance of a proper and solid diagnosis and identifying the patients that are appropriate for Xywav.
And really about the fact that Xywav is approved to treat the full condition of idiopathic hypersomnia, not just the excessive daytime sleepiness that they have been treating for a number of years with off-label stimulus in weight-promoting agents. And really important at the core of that as well, since they’ve been so focused on the daytime symptom of excessive daytime sleepiness is reminding them that idiopathic hypersomnia is actually a 24-hour condition. And that Xywav can address multiple symptoms of idiopathic hypersomnia.
So an important occasional effort there, and we’re gaining traction. Patients so far have been reporting that they’re quite pleased with the comprehensive and customized support that they’re receiving from Jazz during the path to access. So overall, we’re feeling really good, remaining very confident in our ability to maximize the potential of Xywav in this really underserved market.
Operator
Your next question comes from the line of Jason Gerberry with Bank of America. Your line is now open.
Jason Gerberry — Bank of America — Analyst
Hey guys, thanks for taking my questions. Just a question on the step-up — the meaningful step-up in the Hikma royalty in second half. Is that driven off of the assumption that the Hikma AG volumes will step up in a big way and thus their sales? Or is it more just that the royalty rate spikes up in the second half? Or is it just sort of an accounting convention where you’re realizing revenue and it may not perfectly align with the period which is captured? And then also just on the once-slightly oxybate, would you expect that to have to be stepped through the AG generics, just payers historically are reluctant to pay for convenience? Thanks.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes. On the first part of the question, Jason, it’s pretty straightforward. The emphasis we’re trying to put there is really that the royalty rate is expected to be meaningfully higher in the second half of the year. It’s not really a timing or accounting thing. Hikma has been adding patients over time, so they probably have more patients at the end of a period than at the beginning of a period. So that will contribute, too. But the royalty rate is meaningfully different. And on the payer side in sort of high oxybate space and how they might handle that, Kim, maybe I’ll come to you.
Kim Sablich — Executive Vice President and General Manager, United States
Sure. So we started out the year and we continue to experience greater than 90% of patients — commercial patients having payer coverage, formulary for Xywav. And we anticipate that to continue. We’ve been educating payers for some time now about the importance of reducing sodium and we do believe that payers are generally understanding the importance of that reduction.
And they’re seeing the fact that oxybate — Xywav is the oxybate market leader with more than half of all oxybate patients on Xywav and the fact that we’ve continued to grow this leading position over the high sodium oxybate. So we anticipate that as other high sodium oxybates, including the high sodium AG oxybator added to formularies. But we expect Xywav to maintain broad commercial coverage.
Operator
And your next question comes from the line Joseph Thome with Cowen. Your line is now open.
Joseph Thome — TD Cowen — Analyst
Hi, there. Good afternoon and thank you for taking my question. Maybe one on the pipeline for JZP150 and PTSD since we’re going to see those data this year. Maybe what sort of change in the CAT5 [Phonetic] scale do you think is clinically meaningful or would support additional investment in this program? And placebo respense rates are — they can be historically pretty variable in neuropsych indications. So is there anything that you can do in the context of the Phase 2 to try and minimize placebo response? Thanks.
Robert Iannone — Executive Vice President, Global Head of Research and Development
Sure. I’d be happy to take that.
Joseph Thome — TD Cowen — Analyst
Yes. Rob, over to you on that one.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes. Rob, over to you on that one.
Robert Iannone — Executive Vice President, Global Head of Research and Development
Yes. Thanks, Bruce, happy to take the question. So on the first part, we haven’t said exactly what we think would be clinically meaningful, but we certainly had discussions with FDA and key experts in this field that the study is well powered with the two dose levels that we’ve included and to your point, it’s a well-controlled design with placebo. We certainly think the level of severity in the patients that we’re recruiting in the well-established endpoint will allow us to differentiate from any placebo effect that you might see in that particular population is pretty severe upon study entry.
Operator
Your next question comes from the line of Brandon Folkes with Cantor Fitzgerald. Your line is now open.
Brandon Folkes — Cantor Fitzgerald — Analyst
All right, thanks for taking my question. Maybe just following on from an earlier question about the IH market. Can you maybe just elaborate a little bit on the willingness you’re seeing in the field of prescribers to use a sleep-promoting agent for the IH patient, especially those patients with heavy sleep inertia are you seeing prescribers initially try it with some patients with less intense morning sleep inertia? Just any color there on that education you called out for prescribers. Thank you.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Kim?
Kim Sablich — Executive Vice President and General Manager, United States
Sure. So I think if there are physicians out there that are hesitant to use a sleep-promoting agent that just highlights the education that we need to do in this marketplace. We’re, as I mentioned earlier, working to educate prescribers that IH is actually a 24-hour condition and that we can address the multiple both daytime and nighttime symptoms of IH. And once they understand that the daytime symptoms, including sleep inertia that you mentioned are the result of poor sleep quality at night or what we call nonrestorative sleep. They understand why treating with Xywav at nighttime makes sense. So it’s — we’re making progress there, and education is key to changing their understanding and their beliefs.
Operator
And your next question comes from the line of Amy Fadia with Needham and Company. Your line is now.
Amy Fadia — Needham and Company — Analyst
Great, thanks for taking my question. I have one question and one follow-up. Just on suvecaltamide, looks like the endpoint that you’re studying is basically the same as what Practo studied for the study that they reported earlier this year, where some of the performance with the PS scores were [Technical Issues]. And so I was just curious what you thought you might see from your study and efficacy endpoint that you expect to continue to evaluate going forward?
And just as a follow-up to the dynamic in the oxybate market, is it fair to say that there aren’t really influencing switches to the generic, and it really boils down to physician choice? So in that case, who is really taking the generic Xyrem? Thank you.
Bruce C. Cozadd — Chairman and Chief Executive Officer
So Rob, let’s come to you first on suvecaltamide.
Robert Iannone — Executive Vice President, Global Head of Research and Development
Yes. So thanks for the question. We feel as though we learned a lot from TCOM study, that was the Phase 2a study, in a number of respects, including not only the endpoints, but how to measure the endpoints. And we certainly noticed that it can be challenging to assess performance aspects of the TETRAS through a remote server. So in our trial, we’re not doing that. But overall, the combined TETRAS endpoints having to do with activities of daily living and performance scale, is agreed upon with the FDA and is certainly something we’re able to evaluate in our TCOM study, and we have confidence around our drug. And I think you’re highlighting differences in trial designs potentially, but I would also highlight differences in drugs.
Our agent is a state dependent CAT3 and that’s critical because it allows you potentially to push the dose into higher efficacious ranges given the differential activity on pathologic calcium ion channels versus normal vesting state channels. So we think we have a differentiated asset. We think we’re able to push the dose and evaluate those three doses in a Phase II design that’s supported by our prior data. And Kim, on the AG uptake, you want to make a comment on that?
Bruce C. Cozadd — Chairman and Chief Executive Officer
And Kim, on the AG uptake, you want to make a comment on that?
Kim Sablich — Executive Vice President and General Manager, United States
Yes, sure. I mean, so we don’t have exact data on that. What I’ll say is that we’re continuing to see nice uptake as Bruce said of Xywav in the face of the AG. Switching dynamics can happen in a number of places. They can happen with the payer, which I don’t think we’re really seeing is the case right now. They can happen in the HCP offer, they can even actually happen at a pharmacy. We have talked about that Xywav in particular, is not therapeutically equivalent or AB-rated. So we don’t anticipate for switching at the pharmacy with Xywav, but that is certainly a place where switching can happen from Xyrem to the AG.
Operator
Your next question comes from the line of Balaji Prasad with Barclays. Your line is now open.
Balaji Prasad — Barclays — Analyst
Hi, good evening. Just two quick ones from me. Firstly, could you comment on the access that you have to the neurologists and physicians with regard to Epidiolex? And your thoughts around upside or commercial scope for the rest of the year from an access perspective? Thanks. And secondly, a minor question, should we anticipate any further updates on the — on your litigation with Avadel post the delisting direction that you received from the court? Thank you.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes. I’ll take the second part of the question first. I’ll take the second part of the question first, Dan, and just say that we’re not going to comment on ongoing litigation. But Dan, why don’t you talk about Epidiolex access sort of worldwide?
Daniel N. Swisher — President and Chief Operating Officer
Yes. Just sort of thinking more broadly about Epidiolex the 20% year-over-year growth is great, and we remain confident that we’re near blockbuster status on that brand. In both markets, we’ve got strong HCP engagement, face to face engagement. We’ve got great access as we had some wins coming in to the U.S. market. And so it’s — we’ve always had the quantity of access, but now we’ve got the quality of access.
In Europe, France was the last of the five major countries to get access to, and we’re continuing to drive in the smaller markets, both reimbursement as well as TSC reimbursement for that indication. So I think the stage is well set with the face-to-face interactions, the ability to talk to the HCPs not only about the clinical rationale, thanks to the seizure benefit and the combination of Clobazam but also some of the BECOME data from caregivers that was shared, which also had behavioral and cognition outcome.
And then there’s the areas that I mentioned in the presentation or the prepared remarks about additional areas of growth with enhanced focus with adults. Adults were also getting to those physicians had been impacted by COVID an we see that plus long-term care as an area to further double down on as well as optimal dosing, etc. So I think the stage is well set, and we’re pleased with the year-over-year growth and where the brand is going for 2023.
Operator
The next question comes from Madhu Kumar with Goldman Sachs. Your line is now open.
Madhu Kumar — Goldman Sachs — Analyst
Hey, thanks for taking our question. And maybe on the corporate and business development front, how do you think about kind of the boundary between commercial versus near commercial assets? As each quarter moves forward towards 2025, is there a sense that like if you get to a certain point, it really shift from commercial or near commercial to really wanting to be commercial assets to kind of contribute meaningfully to Vision 2025?
Kim Sablich — Executive Vice President and General Manager, United States
Yeah, thanks for the question. I would say, our primary focus is ensuring that we’re targeting assets that we think can have a really meaningful benefit for patients and meaningful impact and therefore benefit our business and our shareholders. With respect to that. On commercial or near commercial, it really depends on the asset, it depends on the nature of the underlying business that that’s an M&A type of opportunity where you’re gaining access to a significant amount of expertise that you’re going to continue or whether we’re looking at something that we can essentially left and drop right into our footprint.
So our focus is essentially the long-term value generation, durability of the asset, how it fits into our overall portfolio. And we do think there are opportunities to ensure that we’re hitting our Vision 2025 goal, but we’re not focused myopically just on that goal. We’re focused on broader growth and the longer-term sustainability and enhanced value.
Operator
Your next question comes from the line all Gregory Renza with RBC Capital Markets. Your line is now open.
Gregory Renza — RBC Capital Markets — Analyst
Great, good afternoon, Bruce and team, congrats on the progress. Thanks for taking my question. Bruce, maybe just spinning back to Xywav and as you go market with the low sodium messaging, which we acknowledge is rather intuitive. And with respect to just the simplicity of that messaging, I’m just curious what barriers would you point to that you think are perhaps underappreciated by investors and others as that messaging gain traction and pull-through with Xywav? Thanks so much.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Kim, why don’t I let you take this one?
Kim Sablich — Executive Vice President and General Manager, United States
Sure. So at this point, we do feel that our low sodium messaging is resonating with healthcare providers and with many patients as well, I think, as evidenced by the amount of patients that have been transitioned to or started on Xywav. That being said, as we’ve brought most subscribers onboard, and many of them have switched a good portion of their patients, the most common barrier that we really hear — two barriers that we hear from a prescriber: either one, I’ve offered it to my patient and they don’t want to switch because Xyrem has changed their lives.
We should never underestimate how much patients love their Xyrem and just don’t want to take any chance no matter what you tell them about the product being the same act of moiety in terms of switching products. So we’re continuing to work on that patient side of things and educating patients about Xywav and making nice progress over time.
The other reason that we hear most is that in the smaller healthcare practices, they feel they just don’t have the means to do the transitioning of the patients. So we do see these offices starting patients on Xywav, and they believe in sodium reduction. But it does take some work to transition patients over. No problem for the larger offices with plenty of staff. But in some of these smaller offices, they just feel that they don’t have the manpower to do that.
Operator
Your next question comes from the line of Akash Tewari with Jefferies. Your line is now open.
Ivory — Jefferies — Analyst
Hi, this is Ivory [Phonetic] on for Akash. Thanks for taking our question. So I guess for the guidance, if the current trend in Q1 continued for the rest of this year, I guess maybe 250 IH patients add, 500 Xywav narcolepsy patients and over 1,000 Xyrem patients lost and assume the same year-over-year Epidiolex growth rate as what you had for last year, your franchise could trend to the lower end of fiscal year guidance, I guess what do you think we are missing here? And then just a quick one on orexin. So Alchmi said they will use different doses for narcolepsy type-1 and 2 patients for atop impact and doses for type 2 patients will be several dose higher. And also the aim to dose to be able to make I guess what’s your view on this comment? And what dosage range are you targeting right now for 441? Thank you.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes, I’ll take the first part and then come to Rob and just say our guidance coming into the year was a couple of months ago and was at the franchise level, neuroscience and oncology, we didn’t get into product level. And as we’re saying today, we’re very pleased with the way the first quarter progressed. And we think we’re right in line with all our expectations to achieve that overall guidance. So we’re not going to get more specific on that. Rob, maybe you could take the orexin part of the question?
Robert Iannone — Executive Vice President, Global Head of Research and Development
Yes. And the question I heard was, do we expect the dose to be different across patient populations? So correct me if I didn’t hear that. I would say the dose, of course, depends on the drug itself and factors such as high availability and potency, etc., etc. But within any given drug, there certainly is the possibility that different doses might be needed across different populations. We know that the relative level of orexin in the brain may differ between NT-1 and NT-2 or other sleepy populations because we’re certainly interested in other populations as well. As you know, we have an ongoing program where we’re evaluating and learning effects in healthy volunteers. And ultimately use those data to transition to patients to understand best for 441, but the most appropriate dosing would be in different patient populations.
Operator
Your next question comes from the line of Greg Fraser with Truist Securities. Your line is now open.
Greg Fraser — Truist Securities — Analyst
Thank you. Good afternoon folks. Just following up on the Xywav survey. Did the survey include physicians that haven’t yet prescribed Xywav as well as current Xywav prescribers? And for those that plan to increase their prescribing of Xywav for IH, what were some of the key reasons behind the predictions? I’m curious to hear your thoughts about diagnosis rates growing, patient awareness growing, any additional color on the survey learnings would be helpful. Thank you.
Kim Sablich — Executive Vice President and General Manager, United States
Sure. Happy to do that. Yes, I do believe the survey was of specialists in general. So that increase would mean both those who’ve tried it and those who have yet to try it. In terms of — I don’t have my fingertips within the survey, we ask the reasons why, but I can tell you based on more qualitative feedback that we’ve had from physicians that the main reason that they are going to continue to use more of it is that it’s actually performing in line with what they expected from the Phase 3 clinical trial results, which were better than health care provider community anticipated.
They were very excited about those results, and they’re very happy to see that it’s performing in line with those results, and they’re getting positive feedback from their patients. And along with that the coverage from the payers has been there and the patient experience in getting on the product, all of that has been very positive.
In line where they have lots of these patients, and they’ve had really very little to be able to treat with them than with other than off-label weight-promoting agents and stimulants over the years, and many of those patients taking those still are not where they want them to be clinically. So that’s the simple story there that we’re hearing out in the marketplace.
Operator
Your next question comes from the line of Jeff Hung with Morgan Stanley. Your line is now open.
Jeff Hung — Morgan Stanley — Analyst
Thanks for taking my question. You mentioned that 60% of U.S. providers are using Epidiolex earlier in the treatment algorithm. What do you think it will take to further drive this in a greater proportion of providers? And what kind of initiatives do you have to help accomplish those? Thanks.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Kim, do you want to start on that one?
Kim Sablich — Executive Vice President and General Manager, United States
Yes. I can speak from the U.S. And again, we are quite pleased with how Epidiolex has been coming along not just this quarter, but the past year and 20% growth year-over-year is very rewarding after years of being under COVID and not being able to interact with this community that’s still quite new to Jazz. And so key to that really is continuing to have a very high-level engagement with our customers that was absent there for a number of years in terms of access to treatment centers and physicians’ offices.
We’re having some really great discussions and seeing the light bulb go off with quite a few of them and more prescribers coming on board. But in terms of driving growth moving forward, that’s very encouraging is that we’ve got some really great clinical data, the data we’ve been out there with for about a year now in terms of showing the great impact that you can have in combining Clobazam with Epidiolex. We’re really getting a lot of traction with that in the marketplace. It’s getting HCPs really to reconsider why they’re not using more of it — or using it earlier in the treatment algorithm as that 60% shows. And then layer on top of that, earlier this year, we started to go out there and talk about more than just seizure control through this care driver survey called BECOME.
And showing HCPs quantitatively what they’ve actually been hearing from caregivers since the launch of Epidiolex, and that is that the caregiver sees improvements in behavior and cognition in the patients that they’re caring for. So that combined with, I’d say the adult setting, particularly the long-term care setting in the U.S. was slower to open up as many institutions were post-COVID.
So we’ve been able more recently to get in there, and we’re excited about more fully penetrating the adult market, particularly in the long-term care setting. And then last thing on the U.S., I’ll say is that HCPs are still underdosing this product. They’re not achieving optimal dosing, which is not achieving the optimal outcome for the patients. So we’re continuing to deliver and putting out there some new programs to really educate them on what optimally dosing Epidiolex looks like, so they can have an even more positive experience with it moving forward. So that’s within the U.S. And then obviously, we’ve a number of ex-U.S. launches expected this year.
Daniel N. Swisher — President and Chief Operating Officer
And Kim, this is Dan. Just to add into it as we see Epidiolex as one of our core, core growth drivers going into Vision 2025 and beyond. We’re really pleased with the real-world performance and assisting physicians that are in a multi-pharmacy setting to change their habits and appreciate the unique profile of Epidiolex. So in addition to all the great work that Kim and her team are doing in the U.S. and Sam Pearce is doing in Europe, we’re also trying to leverage our full ability from an evidence generation.
Some of that’s going to be with new indications, such as we have with EMAS in terms of exploring additional seizure types. Some of it is going to be observational studies. And some of it’s going to be leveraging now an increasing number of medical records to show some of those trends that with higher and more optimal dosing, you can get to better efficacy sooner. And then exploring what we saw in the caregiver survey, for example, of the beyond seizure benefit and seeing that in additional clinical data. So super excited for this evidence generation that we’ve got it should support all regions in the long-term growth of the product.
Operator
Your next question comes from the line of Annabelle Simons with Stifel. Your line is open.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Annabelle, we’re not hearing you.
Operator
Your line is open, Annabelle.
Bruce C. Cozadd — Chairman and Chief Executive Officer
All right. Operator, maybe we’ll move on to the next one.
Operator
All right. Your next question. From the line of Ash Verma with UBS. Your line is now open.
Ash Verma — UBS — Analyst
Hi, thanks you ask questions. I have two. So with respect to Avadel’s Lumryz in your view, could payers push narcolepsy patients towards using a once-nightly product if Avadel comes in with a significant price discount? And then second, like do you think Lumryz can also be used off-label for IH? As we understand, IH patients can particularly struggle with taking a second dose, at least like based on our KOL feedback, they’re getting to hear that up to one-third of IH patients can skip their second added dose. I don’t know if you have any data that can elaborate on that point.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yeah, Kim, do you want to jump in on this? Sure. I’d be happy to. And we talked a little while ago about payers in general. So really, our strategy there is not changing. Again, we’ve been talking to payers for some time about the benefits of low-sodium Xywav. And we do believe that payers are understanding the importance of that, and they understand that HCPs are increasingly choosing Xywav and that greater than 50 patients are on Xywav today. And they’re enjoying nice rebates on Xywav today. So I really do believe that as other high sodium oxybates come on to the market and they’re ultimately added to formularies that Xywav is going to continue to maintain a broad commercial coverage. You asked about idiopathic hypersomnia. And we don’t expect the approval of FT218 will affect the IH market as it’s not approved for idiopathic hypersomnia. Xywav is still the only FDA-approved therapy for this condition. And I think it’s good to remind you that the Xywav can be administered as either twice nightly or once nightly regimen for IH in adult patients. That’s what the label allows. All right operator, I think we’ve got time for one more question.
Operator
And your last question comes from the line of David Amsellem with Piper Sandler. Your line is now open.
David Amsellem — Piper Sandler — Analyst
Hey, thanks. So wanted to get your thoughts on the potential impact of pitolisant or Wakix on Xywav to the extent that zap product eventually gets approved? And then secondly on the Orexin, I think I’ve asked this before, but I wanted to pick your brain on it. Any thoughts on why you’re dosing it at night? Here it seems a little counterintuitive. So I was wondering if there’s any reason mechanistically or from a PK perspective that you’re doing so? Thank you.
Bruce C. Cozadd — Chairman and Chief Executive Officer
If I understood that question, that was about orexin. Rob, do you want to take that one first?
Robert Iannone — Executive Vice President, Global Head of Research and Development
Yes. I just — I didn’t fully understand it either, Bruce. The question is why would you be dosing orexin at night, I’m sorry, I didn’t follow it.
David Amsellem — Piper Sandler — Analyst
That’s all right. I mean your — the others, I believe there — it’s a Wakix drug. So why are you adjusting it at night?
Robert Iannone — Executive Vice President, Global Head of Research and Development
Oh, in our Phase I.
David Amsellem — Piper Sandler — Analyst
Correct.
Robert Iannone — Executive Vice President, Global Head of Research and Development
We’re leveraging a model in healthy volunteers where you sleep the product healthies and then measure the wakefulness of the intervention when people are — have a high, high propensity for sleep. That turns out to be a pretty good model for disorders of daytime sleepiness like narcolepsy. And so it just gives us an opportunity to learn more about the drug and ultimately select doses when we get into patients, who will then receive the drug during the day.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes. Maybe also start on…
Daniel N. Swisher — President and Chief Operating Officer
And then on — go ahead, Bruce.
Bruce C. Cozadd — Chairman and Chief Executive Officer
Yes. Go ahead, Dan.
Daniel N. Swisher — President and Chief Operating Officer
I was just going to say on pitolisant, I mean we — it’s all going to depend on the data, of course. But the Xywav has got some very powerful efficacy across multiple endpoints to treat the full condition and having a nighttime therapy is resulting in significant benefit through the day, whereas pitolisant similar to the wake-promoting agents will be used during the day, and it’s always going to be a bit of a challenge for the long sleepers because you have to be a wait to take the oral dose.
So we don’t see it as a significant threat or a displacement. But again, more treatment options for these patients, more commercial noise and education around IH would be a benefit for us.
Operator
And we have no further questions at this time. I will now turn the call back over to Bruce Cozadd.
Bruce C. Cozadd — Chairman and Chief Executive Officer
All right. Thanks, operator. So just to wrap, thanks for the wide-ranging questions. I think we hit pretty much all the key topics that we covered in our news release, in our script. I don’t think we got many questions on oncology. I’ll just reiterate, we’re really excited for the growth of our oncology franchise led by Rylaze and Zepzelca. And didn’t get many questions on zanidatamab, but lots of news upcoming there with additional clinical data presentations. And we’re looking forward to progress that program rapidly. Most important, we’re continuing to be focused on Vision 2025. Remember that we’ve got upcoming Phase 2b zanidatamab BTC data at ASCO in June. That’s the first time zani findings are going to be featured during an oral session at a major oncology conference.
And immediately after the presentation, we’re hosting a webcast where Dr. Shubham Pant, who is presenting the data at ASCO who will review findings. We’re also presenting multiple data sets at this year’s American Academy of Sleep Medicine Annual Meeting if any of you are at ASCO or at Sleep, we may see you there. Also note, we’re participating in the upcoming RBC Investor Conference on May 16th. Let me close today’s call by recognizing our Jazz colleagues for their work to deliver new therapeutic options to patients. And I want to thank our partners and shareholders for their continued confidence and support. Thank you all for joining us today.
Operator
[Operator Closing Remarks]